YU47122B - 5-deoksi-5-fluorocitidinski derivati - Google Patents

5-deoksi-5-fluorocitidinski derivati

Info

Publication number
YU47122B
YU47122B YU209188A YU209188A YU47122B YU 47122 B YU47122 B YU 47122B YU 209188 A YU209188 A YU 209188A YU 209188 A YU209188 A YU 209188A YU 47122 B YU47122 B YU 47122B
Authority
YU
Yugoslavia
Prior art keywords
atoms
formula
carbon atoms
fluorocitidinski
deoksi
Prior art date
Application number
YU209188A
Other languages
English (en)
Other versions
YU209188A (en
Inventor
M. Fujiu
H. Ishitsuka
M. Miwa
I. Umeda
K. Yokose
Original Assignee
F. Hoffmann-La Roche & Co. Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche & Co. Ag. filed Critical F. Hoffmann-La Roche & Co. Ag.
Publication of YU209188A publication Critical patent/YU209188A/xx
Publication of YU47122B publication Critical patent/YU47122B/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

5-DEOKSI-5-FLUOROCITIDINSKI DERIVATI, naznačeni time, što imaju opštu formulu (I), u kojoj R1, R2 i R3 nezavisno jedan od drugog označavaju vodonik ili neki radikal koji se lako hidrolizuje pod fiziološkim uslovima i predstavljen je formulom R4CO-, R5OCO- ili R6SCO-u kojoj R4 označava atom vodonika, alkil sa 1-17 C-atoma, cikloalkil sa 3 do 10 C-atoma, alkenil sa 2 do 8 C-atoma, aralkil sa najviše 9 C-atoma ili aril sa najviše 10 C-atoma, dok R5 i R6 označavaju alkil sa 1 do 8 C-atoma ili aralkil sa najviše 9 C-atoma, s tim što bar jedno od R1, R2, R3 mora biti radikal navedene formul, kao i hidrati ili solvata jedinjenja formule.
YU209188A 1987-11-17 1988-11-10 5-deoksi-5-fluorocitidinski derivati YU47122B (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP87116926 1987-11-17

Publications (2)

Publication Number Publication Date
YU209188A YU209188A (en) 1990-08-31
YU47122B true YU47122B (sh) 1994-12-28

Family

ID=8197450

Family Applications (1)

Application Number Title Priority Date Filing Date
YU209188A YU47122B (sh) 1987-11-17 1988-11-10 5-deoksi-5-fluorocitidinski derivati

Country Status (35)

Country Link
US (1) US4966891A (sh)
EP (1) EP0316704B1 (sh)
JP (1) JPH0678350B2 (sh)
KR (1) KR970000241B1 (sh)
CN (1) CN1022688C (sh)
AR (1) AR247217A1 (sh)
AT (1) ATE124951T1 (sh)
AU (1) AU619220B2 (sh)
CA (1) CA1327358C (sh)
CS (1) CS274486B2 (sh)
DE (2) DE10199027I2 (sh)
DK (1) DK170893B1 (sh)
DZ (1) DZ1270A1 (sh)
ES (1) ES2074429T3 (sh)
FI (1) FI89804C (sh)
GR (1) GR3017686T3 (sh)
HK (1) HK1003114A1 (sh)
HU (1) HU199866B (sh)
IE (1) IE883430L (sh)
IL (1) IL88363A0 (sh)
IS (1) IS1895B (sh)
LT (1) LT2185B (sh)
LU (1) LU90769I2 (sh)
LV (1) LV5624A3 (sh)
MC (1) MC1992A1 (sh)
MX (1) MX173347B (sh)
NL (1) NL300045I2 (sh)
NO (2) NO171167C (sh)
NZ (1) NZ226923A (sh)
PH (1) PH25641A (sh)
PT (1) PT89009B (sh)
SU (1) SU1736342A3 (sh)
UA (1) UA19333A (sh)
YU (1) YU47122B (sh)
ZA (1) ZA888428B (sh)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258360B1 (en) * 1989-05-04 2001-07-10 Igen International, Inc. Prodrugs activated by targeted catalytic proteins
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
TW254946B (sh) * 1992-12-18 1995-08-21 Hoffmann La Roche
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
EP0882734B1 (en) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag 5'-Deoxy-cytidine derivatives
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20010051348A1 (en) * 2000-01-28 2001-12-13 Lee Chee Wee Novel ligands and methods for preparing same
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US6774758B2 (en) * 2002-09-11 2004-08-10 Kalyan P. Gokhale Low harmonic rectifier circuit
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
AU2003233586A1 (en) * 2003-05-20 2005-01-21 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising capecitabine and a liposomal platinum complex
CA2550299C (en) * 2003-12-22 2010-03-30 Christopher R. Roberts Process for fluorocytidine derivatives
JP2007523905A (ja) * 2004-02-18 2007-08-23 アストラゼネカ アクチボラグ 化合物
WO2005080359A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Benzamide derivatives and their use as glucokinae activating agents
CN100383128C (zh) * 2004-02-23 2008-04-23 上海迪赛诺医药发展有限公司 N4－氧羰基胞嘧啶衍生物及制备方法与应用
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR101061850B1 (ko) 2004-09-08 2011-09-02 삼성전자주식회사 박막 트랜지스터 표시판 및 그 제조방법
GB0421294D0 (en) * 2004-09-24 2004-10-27 Angiogene Pharm Ltd Bioreductively-activated prodrugs
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
JP2008516935A (ja) 2004-10-16 2008-05-22 アストラゼネカ アクチボラグ フェノキシベンズアミド化合物の製造方法
WO2006084058A2 (en) 2005-02-03 2006-08-10 The General Hospital Corporation Method for treating gefitinib resistant cancer
NO322682B1 (no) * 2005-03-18 2006-11-27 Clavis Pharma Asa Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
WO2006103187A2 (en) * 2005-04-01 2006-10-05 F. Hoffmann-La Roche Ag Method for administration of capecitabine
EP1891069A1 (en) * 2005-05-24 2008-02-27 AstraZeneca AB 2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
AU2006268406C1 (en) 2005-07-09 2011-02-24 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
JP2009500442A (ja) * 2005-07-09 2009-01-08 アストラゼネカ アクチボラグ ２型糖尿病を処置するためのグルコキナーゼのモジュレーターとしての２−ヘテロシクリルオキシベンゾイルアミノヘテロシクリル化合物
EP2027113A1 (en) * 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
CN100569790C (zh) * 2005-07-15 2009-12-16 上海奥锐特国际贸易有限公司 合成n4-酰基-5＇-脱氧-5-氟胞苷衍生物的方法
ES2384267T3 (es) 2005-07-21 2012-07-03 Nuvo Research Ag Soluciones de clorito estabilizadas en combinación con fluoropirimidinas para el tratamiento del cáncer
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
WO2007056118A1 (en) 2005-11-04 2007-05-18 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
CL2007003061A1 (es) 2006-10-26 2008-08-01 Astrazeneca Ab Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2.
CN100425617C (zh) * 2006-10-31 2008-10-15 浙江海正药业股份有限公司 一种含氟嘧啶类化合物烷氧羰酰化的方法
US20100094009A1 (en) 2006-12-21 2010-04-15 Mccabe James Novel crystalline compound useful as glk activator
ITMI20070435A1 (it) 2007-03-05 2008-09-06 Innovate Biotechnology Srl 2',3'-di-o-acil-5-fluoronucleosidi
EP2137201A2 (en) * 2007-04-20 2009-12-30 Dr. Reddy's Laboratories Ltd. Process for preparing capecitabine
EP2164856A1 (en) * 2007-06-01 2010-03-24 Synthon B.V. Processes related to making capecitabine
WO2009042064A2 (en) 2007-09-21 2009-04-02 Nektar Therapeutics Al, Corporation Oligomer-nucleoside phosphate conjugates
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US20090209754A1 (en) * 2008-01-03 2009-08-20 Macdonald Peter Lindsay Process for the preparation of capecitabine
EP2915532B1 (en) 2008-06-17 2016-10-19 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
ES2614912T3 (es) 2008-08-04 2017-06-02 Wyeth Llc Combinaciones antineoplásicas de 4-anilino-3-cianoquinolinas y capecitabina
AU2009278929B2 (en) 2008-08-04 2012-07-05 Astrazeneca Ab Pyrazolo [3,4] pyrimidin-4-yl derivatives and their uses to treat diabetes and obesity
WO2010065586A2 (en) * 2008-12-02 2010-06-10 Dr. Reddy's Laboratories Ltd. Preparation of capecitabine
US8603999B2 (en) 2008-12-05 2013-12-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
CN101787066B (zh) * 2009-01-23 2013-07-31 高峰 阿糖胞苷衍生物及其在抗癌抗肿瘤中的用途
GB0902406D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
EP3000467B1 (en) 2009-04-06 2023-03-01 Wyeth LLC Treatment regimen utilizing neratinib for breast cancer
AR076221A1 (es) * 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
CN101875680B (zh) * 2009-04-28 2012-07-25 上海信旗医药科技有限公司 一种核苷类化合物及其制备方法和应用
WO2011010967A1 (en) * 2009-07-23 2011-01-27 Scinopharm Taiwan Ltd. Process for producing flurocytidine derivatives
HUE040107T2 (hu) 2010-03-12 2019-02-28 Genzyme Corp Kombinációs terápia mellrák kezelésére
AU2013243953A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151666A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of biologics and proteins associated with human disease
MX2015003513A (es) 2012-09-26 2015-07-17 Hoffmann La Roche Compuestos ciclicos eter pirazol-4-il-heterociclil-carboxamida y metodos de utilizacion.
CN104955458A (zh) 2012-11-07 2015-09-30 Z·索 取代的吉西他滨芳基酰胺类似物和使用所述类似物的治疗方法
EP2971033B8 (en) 2013-03-15 2019-07-10 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
EP2968382B1 (en) * 2013-03-15 2018-03-07 Nucorion Pharmaceuticals, Inc. Substituted gemcitabine bicyclic amide analogs and treatment methods using same
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CN103450301B (zh) * 2013-09-09 2015-09-09 南通大学 法尼基硫代水杨酸-核苷缀合物、其制备方法及其医药用途
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN109414438A (zh) * 2016-06-28 2019-03-01 塞尔利克斯生物私人有限公司 用于治疗癌症的组合物和方法
WO2018129533A1 (en) 2017-01-09 2018-07-12 Shuttle Pharmaceuticals, Llc Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CN110831605A (zh) 2017-04-26 2020-02-21 托马斯·I.·卡尔曼 多靶标的核苷衍生物
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
EP3737376B1 (en) 2018-01-09 2024-04-17 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human diseases
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
CN111801339A (zh) * 2018-01-19 2020-10-20 纽科利制药公司 5-氟尿嘧啶化合物
WO2020026054A1 (en) * 2018-08-03 2020-02-06 Cellix Bio Private Limited Compositions and methods for the treatment of cancer
CN109651467A (zh) * 2019-01-15 2019-04-19 齐鲁天和惠世制药有限公司 一种卡培他滨杂质及其制备方法
JP2023523415A (ja) 2020-04-21 2023-06-05 リガンド・ファーマシューティカルズ・インコーポレイテッド ヌクレオチドプロドラッグ化合物
WO2022020811A1 (en) 2020-07-24 2022-01-27 Strand Therapeutics, Inc. Lipidnanoparticle comprising modified nucleotides
CA3204373A1 (en) 2021-01-08 2022-07-14 Strand Therapeutics Inc. Expression constructs and uses thereof
WO2023212618A1 (en) 2022-04-26 2023-11-02 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3404144A (en) * 1965-12-23 1968-10-01 Research Corp 1-beta-d-arabinofuranosyl-5-fluorocytosine compounds
GB1379410A (en) * 1971-06-08 1975-01-02 Upjohn Co 1-beta-d-arabino-furanosyl-n4-alpha-aminoacylcytosines
JPS52153977A (en) * 1976-06-11 1977-12-21 Daikin Ind Ltd Synthesis of 5-fluorouracil and its derivatives
US4071680A (en) * 1976-12-20 1978-01-31 Hoffmann-La Roche Inc. 5'-Deoxy-5-fluoropyrimidine nucleosides
CH633810A5 (en) * 1978-01-01 1982-12-31 Hoffmann La Roche Novel nucleosides and process for their preparation
FR2528311B1 (fr) * 1982-06-14 1985-06-14 Synthelabo Compositions pharmaceutiques a base de xylosides et lyxosides de bases puriques et pyrimidiques
JPS61112093A (ja) * 1984-11-05 1986-05-30 Wakunaga Seiyaku Kk ヌクレオチド誘導体

Also Published As

Publication number Publication date
HU199866B (en) 1990-03-28
UA19333A (uk) 1997-12-25
NO885106D0 (no) 1988-11-16
FI885329A (fi) 1989-05-18
PT89009B (pt) 1993-02-26
JPH01153696A (ja) 1989-06-15
DE3854148D1 (de) 1995-08-17
NL300045I2 (nl) 2002-01-02
NO885106L (no) 1989-05-18
US4966891A (en) 1990-10-30
FI89804B (fi) 1993-08-13
KR890008162A (ko) 1989-07-10
ES2074429T3 (es) 1995-09-16
FI89804C (fi) 1993-11-25
DK640388D0 (da) 1988-11-16
AU2516888A (en) 1989-05-25
CS747588A2 (en) 1990-09-12
DE10199027I1 (de) 2001-08-02
NO171167B (no) 1992-10-26
CS274486B2 (en) 1991-04-11
DZ1270A1 (fr) 2004-09-13
MX13836A (es) 1993-10-01
EP0316704A2 (de) 1989-05-24
YU209188A (en) 1990-08-31
AR247217A1 (es) 1994-11-30
IS3412A7 (is) 1989-05-18
NO171167C (no) 1993-02-03
PH25641A (en) 1991-08-21
EP0316704B1 (de) 1995-07-12
HUT48267A (en) 1989-05-29
IS1895B (is) 2003-10-20
NO2001013I2 (no) 2006-05-01
LT2185B (lt) 1993-10-15
NZ226923A (en) 1990-10-26
CA1327358C (en) 1994-03-01
JPH0678350B2 (ja) 1994-10-05
SU1736342A3 (ru) 1992-05-23
HK1003114A1 (en) 1998-10-09
PT89009A (pt) 1988-12-01
CN1033183A (zh) 1989-05-31
IE883430L (en) 1989-05-17
LU90769I2 (fr) 2001-07-02
KR970000241B1 (ko) 1997-01-08
DK170893B1 (da) 1996-03-04
MX173347B (es) 1994-01-03
DE10199027I2 (de) 2002-01-31
LV5624A3 (lv) 1994-05-10
MC1992A1 (fr) 1989-11-30
ZA888428B (en) 1989-06-28
GR3017686T3 (en) 1996-01-31
FI885329A0 (fi) 1988-11-17
DK640388A (da) 1989-05-18
ATE124951T1 (de) 1995-07-15
NL300045I1 (nl) 2001-08-01
AU619220B2 (en) 1992-01-23
IL88363A0 (en) 1989-06-30
EP0316704A3 (en) 1990-11-22
CN1022688C (zh) 1993-11-10

Similar Documents

Publication Publication Date Title
YU47122B (sh) 5-deoksi-5-fluorocitidinski derivati
DE3684574D1 (de) Rapamycin-vorlaeufer.
NO163819C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1h-imidazo(4,5-c)kinolin og derivater derav.
DK235690A (da) Platin(ii)-komplekser, deres fremstilling og anvendelse som antitumormidler
ES8507090A1 (es) Procedimiento para la obtencion de nuevas 1, 5-benzotiacepinas
DK391182A (da) Heterocycliske forbindelser, deres fremstilling og anvendelse
DK120483A (da) Phenylpiperazinderivater og fremgangsmaade til deres fremstilling
IL90559A0 (en) Analgetic derivatives of phenothiazine
ES476168A1 (es) Procedimiento para la preparacion de nuevas imidazo-isoquinoleindionas.
ES8801205A1 (es) Un procedimiento para la produccion de una isatina y una sal de la misma
DE3870468D1 (de) Ergolinylheterocyclen.
EP0134112A3 (en) Pharmaceutical composition for prophylaxis or treatment of ketosis in livestock
AU597923B2 (en) 5-aminoalkyl-beta-carboline derivatives, their production and their use as drugs
HUT60261A (en) Process for producing piperazine derivatives and pharmaceutical compositions comprising same
GR3008034T3 (sh)
DE3271277D1 (en) Tropyl and pseudotropyl alkyl-benzoates and their use in migraine treatment
ES395496A1 (es) Procedimiento para la obtencion de derivados de 4-(3-amino-propoxi) indol.
ES8403467A1 (es) Procedimiento para la obtencion de derivados de oximino-cian-acetamida sustituidos por azol.
NO922732L (no) 3,4-dehydropiperidinderivater